Jeffrey Infante, MD
SCRI Development Innovations, LLC · Sarah Cannon Research Institute (SCRI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jeffrey Infante, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:53 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT02096341 · A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001EpicentRx, Inc. · terminated · Malignant Solid Tumor, Lymphomas · principal investigator
- Ph1NCT01359982 · Safety and Pharmacokinetic Study of RRx-001 in Cancer SubjectsEpicentRx, Inc. · completed · Malignant Solid Tumor, Lymphomas · principal investigator
- Ph1NCT01247168 · An Open-Label, Dose-Escalation Study of AZD2461AstraZeneca · completed · Refractory Solid Tumors, Cancer Tumor · principal investigator
- Ph1NCT00733031 · Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918AstraZeneca · terminated · Cancer,, Solid Tumors, Advanced Solid Malignancies · principal investigator
- Ph1NCT00600496 · A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)AstraZeneca · completed · Breast Cancer, Breast Neoplasms, Colon Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.